myNEO Therapeutics has developed a unique platform to design neoantigen-driven therapies for cancer patients, using digital tumor fingerprints from a small piece of tumor tissue and healthy blood.
I was asked to develop business models for the different offerings and market segments in which myNEO Therapeutics was active. I also supported important negotiations in the personalized therapy market and the off-the-shelf cancer vaccine market.
Katrien worked with us for 8 months during 2021-2022, and helped myNEO across various fields in business development. She was a driving force to add more structure to our ongoing BD activities, both initiating recurrent meetings and setting up proper responsibility flows within the existing team throughout the process.
Katrien helped us to stratify different prospects into commercial categories, and choose a clear focus for long-term value generation. Lastly, she was heavily involved in setting-up and negotiating the terms of multiple large commercial license agreements on the myNEO technology with biotechnology partners.
